Newer Insulin Therapies for Management of Type 1 and Type 2 Diabetes Mellitus

Consultant Pharmacist

Volumn 18, Issue 5, 2003, Pages 454-465

  Plum, Mary Beth F ^a   Sicat, Brigitte L ^a   Brokaw, Deborah K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Inhaled insulin; Insulin; Insulin analogs; Insulin aspart; Insulin glargine

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; NEUTRAL INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

CLINICAL TRIAL; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MANUFACTURE; DRUG SAFETY; EDEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LIPODYSTROPHY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRURITUS; PUBLICATION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN IRRITATION; TREATMENT OUTCOME;

EID: 0442294908     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(Suppl 1):S5-20. Committee report.
2. American Diabetes Association. Diabetes facts & figures (http://www.diabetes.org: 80/main/application/commercewf?origin=*.jsp& event=linkB1). Accessed Mar 2003.
3. American Diabetes Association. Screening for diabetes. Diabetes Care 2003;26(Suppl 1):S21-24.
4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-32.
5. Powers A. Diabetes mellitus. In: Braunwald E, Fauci AS, Kasper DL et al, eds. Harrison's principles of internal medicine. 15th edition. NewYork: McGraw-Hill; 2001. pp. 2109-37.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
7. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 22). Lancet 1998;352:837-53.
8. United Kingdom Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
9. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002;25(Suppl1): S33-49.
10. White JR, Campbell RK, Hirsh I. Insulin analogues: new agents for improving glycemic control. Postgrad Med 1997;101:58-70.
11. Oki JC, Isley WL. Diabetes mellitus. In: Dipiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 5th edition. NewYork: McGraw-Hill; 2002. pp. 1335-58.
12. DeFronzo RA. Current management of diabetes mellitus. St. Louis, MO: Mosby; 1998. pp. 36-49, 108-16.
13. McEvoy GK, editor. AHFS drug information 2001. Bethesda, MD: American Society of Health-System Pharmacists; 2001.
14. Buse J. Insulin glargine (HOE901) - first responsibilities: understanding the data and ensuring safety. Diabetes Care 2000;23:576-8.
15. Heinemann L, Linkeschov RA, Rave K et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9.
16. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-6.
17. Rosenstock J, Schwartz SL, Clark CM et al. Basal insulin therapy in type 2 diabetes. Diabetes Care 2001;24:631-6.
18. Ratner RE, Hirsch IB, Neifing JL et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-43.
19. Aventis Pharmaceuticals Inc. Lantos® package insert. Kansas City, MO: Feb 2001.
20. 2002 DrugTopics red book. Montvale, NJ: Thompson Medical Economics; 2002.
21. Clement S, Howen-Wright H. Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: a case report. Diabetes Care 2002;25:1479-80.
22. Setter SM, Corbett CF, Campbell RK et al. Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother 2000;34:1423-31.
23. Novo Nordisk Pharmaceutics Inc. NovoLog® package insert. Princeton, NJ: Dec 2001.
24. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. Diabetes Care 1999;22:801-5.
25. Raskin P, Guthrie RA, Leiter L et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23:583-8.
26. Eli Lilly and Company. Humalog® package insert. Indianapolis: May 2000.
27. Novo Nordisk. Novo Nordisk's rapid-acting insulin analog now available in disposable prefilled pen [news release]. Princeton, NJ: Mar 2003.
28. Novo Nordisk. New insulin analog formulation with disposable prefilled doser from Novo Nordisk is now available in the Unied States [news release]. Princeton, NJ: Sep 2002.
29. Cefalu WT, Skyler JS, Kourides IA et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203-7.
30. Laube BL. Treating diabetes with aerosolized insulin. Chest 2001;130:99S-106S.
31. Skyler JS, Cefalu WT, Kourides IA et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet 2001;357:331-5.
32. Henry RH, Mudaliar SRD, Howland WC III et al. Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes 2003;26:764-9.
33. Himmelmann A, Jendale J, Mellem A et al. The impact of smoking on inhaled insulin. Diabetes Care 2003;26:677-82.
34. Kelly K, Cohen MR, Smetzer J, eds. Combination insulin products increase opportunity for errors. ISMP Medication Safety Alert/Ambulatory Pharmacy Edition (Mar 2003):3.